Patents by Inventor Luis GUACHALLA

Luis GUACHALLA has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20230220055
    Abstract: The invention provides for an isolated antibody that specifically recognizes a galactan-III epitope of the lipopolysaccharide (LPS) O-antigen structure of Klebsiella pneumoniae, which epitope is incorporated in galactan-III repeating units, wherein the galactan-III repeating unit is a branched galactose homopolymer of Formula (I). The invention further provides for a pharmaceutical or diagnostic preparation comprising said antibody, and a method of producing said antibody.
    Type: Application
    Filed: August 16, 2022
    Publication date: July 13, 2023
    Applicant: X4 PHARMACEUTICALS (AUSTRIA) GMBH
    Inventors: Valeria SZIJARTO, Gábor NAGY, Luis GUACHALLA, Zehra VISRAM, Eszter NAGY, Jolanta Katarzyna LUKASIEWICZ
  • Patent number: 11466074
    Abstract: The invention provides for an isolated antibody that specifically recognizes a galactan-III epitope of the lipopolysaccharide (LPS) O-antigen structure of Klebsiella pneumoniae, which epitope is incorporated in galactan-III repeating units, wherein the galactan-III repeating unit is a branched galactose homopolymer of Formula (I). The invention further provides for a pharmaceutical or diagnostic preparation comprising said antibody, and a method of producing said antibody.
    Type: Grant
    Filed: November 3, 2015
    Date of Patent: October 11, 2022
    Assignee: X4 PHARMACEUTICALS (AUSTRIA) GMBH
    Inventors: Valeria Szijarto, Gábor Nagy, Luis Guachalla, Zehra Visram, Eszter Nagy, Jolanta Katarzyna Lukasiewicz
  • Publication number: 20210162034
    Abstract: The subject relates to an isolated antibody that specifically binds to O25b antigen of multi drug resistant (MDR) E. coli strains, its medical and diagnostic use, method of producing the antibody, including an isolated nucleotide sequence, plasmids and host cells as used in the production of the antibody; and further an isolated epitope recognized the specific antibody.
    Type: Application
    Filed: February 4, 2021
    Publication date: June 3, 2021
    Applicant: X4 PHARMACEUTICALS (AUSTRIA) GMBH
    Inventors: Eszter NAGY, Gábor NAGY, Valéria SZIJÁRTO, Zoltán MAGYARICS, Irina MIRKINA, Luis GUACHALLA, Adriana BADARAU, Gerhild ZAUNER, Jolanta LUKASIEWICZ
  • Patent number: 10940191
    Abstract: The subject relates to an isolated antibody that specifically binds to O25b antigen of multi drug resistant (MDR) E. coli strains, its medical and diagnostic use, method of producing the antibody, including an isolated nucleotide sequence, plasmids and host cells as used in the production of the antibody; and further an isolated epitope recognized the specific antibody.
    Type: Grant
    Filed: December 21, 2018
    Date of Patent: March 9, 2021
    Assignee: X4 PHARMACEUTICALS (AUSTRIA) GMBH
    Inventors: Eszter Nagy, Gábor Nagy, Valéria Szijárto, Zoltán Magyarics, Irina Mirkina, Luis Guachalla, Adriana Badarau, Gerhild Zauner, Jolanta Lukasiewicz
  • Publication number: 20200339668
    Abstract: A cross-neutralizing monoclonal antibody that specifically recognizes a cross-reactive epitope of the lipopolysaccharide (LPS) antigen structure of Klebsiella pneumoniae, which is an O3b epitope, cross-reacting with an O3a epitope and an O3 epitope, wherein the antibody is characterized by specific CDR sequences or VH and VL sequences.
    Type: Application
    Filed: July 6, 2020
    Publication date: October 29, 2020
    Applicants: X4 Pharmaceuticals (Austria) GmbH, Max-Planck-Gesellschaft zur Förderung der Wissenschaften e. V.
    Inventors: Valeria SZIJÁRTO, Gábor NAGY, Luis GUACHALLA, Katharina RAMONI, Adriana BADARAU, Eszter NAGY, Tim ROLLENSKE, Hedda WARDEMANN, Irina MIRKINA
  • Patent number: 10759848
    Abstract: A cross-neutralizing monoclonal antibody that specifically recognizes a cross-reactive epitope of the lipopolysaccharide (LPS) antigen structure of Klebsiella pneumoniae, which is an O3b epitope, cross-reacting with an O3a epitope and an O3 epitope, wherein the antibody is characterized by specific CDR sequences or VH and VL sequences.
    Type: Grant
    Filed: August 11, 2017
    Date of Patent: September 1, 2020
    Assignees: ARSANIS Biosciences GmbH, Max-Planck-Gesellschaft zur Förderung der Wissenschaften e. V.
    Inventors: Valeria Szijárto, Gábor Nagy, Luis Guachalla, Katharina Ramoni, Adriana Badarau, Eszter Nagy, Tim Rollenske, Hedda Wardemann, Irina Mirkina
  • Publication number: 20190161534
    Abstract: A cross-neutralizing monoclonal antibody that specifically recognizes a cross-reactive epitope of the lipopolysaccharide (LPS) antigen structure of Klebsiella pneumoniae, which is an O3b epitope, cross-reacting with an O3a epitope and an O3 epitope, wherein the antibody is characterized by specific CDR sequences or VH and VL sequences.
    Type: Application
    Filed: August 11, 2017
    Publication date: May 30, 2019
    Applicants: ARSANIS Biosciences GmbH, Max-Planck-Gesellschaft zur Förderung der Wissenschaften e. V.
    Inventors: Valeria SZIJÁRTO, Gábor NAGY, Luis GUACHALLA, Eszter NAGY, Tim ROLLENSKE, Hedda WARDEMANN
  • Publication number: 20190153077
    Abstract: A cross-neutralizing monoclonal antibody that specifically recognizes a cross-reactive epitope of the lipopolysaccharide (LPS) antigen structure of Klebsiella pneumoniae, which is an O3b epitope, cross-reacting with an O3a epitope and an O3 epitope, wherein the antibody is characterized by specific CDR sequences or VH and VL sequences.
    Type: Application
    Filed: August 11, 2017
    Publication date: May 23, 2019
    Applicants: ARSANIS Biosciences GmbH, Max-Planck-Gesellschaft zur Förderung der Wissenschaften e. V.
    Inventors: Valeria SZIJÁRTO, Gábor NAGY, Luis GUACHALLA, Katharina RAMONI, Adriana BADARAU, Eszter NAGY, Tim ROLLENSKE, Hedda WARDEMANN, Irina MIRKINA
  • Publication number: 20190111121
    Abstract: The subject relates to an isolated antibody that specifically binds to O25b antigen of multi drug resistant (MDR) E. coli strains, its medical and diagnostic use, method of producing the antibody, including an isolated nucleotide sequence, plasmids and host cells as used in the production of the antibody; and further an isolated epitope recognized the specific antibody.
    Type: Application
    Filed: December 21, 2018
    Publication date: April 18, 2019
    Applicant: ARSANIS BIOSCIENCES GMBH
    Inventors: Eszter NAGY, Gábor NAGY, Valéria SZIJÁRTO, Zoltán MAGYARICS, Irina MIRKINA, Luis GUACHALLA, Adriana BADARAU, Gerhild ZAUNER, Jolanta LUKASIEWICZ
  • Patent number: 10206992
    Abstract: The subject relates to an isolated antibody that specifically binds to O25b antigen of multi drug resistant (MDR) E. coli strains, its medical and diagnostic use, method of producing the antibody, including an isolated nucleotide sequence, plasmids and host cells as used in the production of the antibody; and further an isolated epitope recognized the specific antibody.
    Type: Grant
    Filed: December 9, 2016
    Date of Patent: February 19, 2019
    Assignee: ARSANIS BIOSCIENCES GMBH
    Inventors: Eszter Nagy, Gábor Nagy, Valéria Szijárto, Zoltán Magyarics, Irina Mirkina, Luis Guachalla, Adriana Badarau, Gerhild Zauner, Jolanta Lukasiewicz
  • Publication number: 20180312576
    Abstract: The invention provides for an isolated antibody that specifically recognizes an epitope of the lipopolysaccharide (LPS) O3b-antigen structure of Klebsiella pneumoniae, which is a O3b-epitope incorporated in O3b-antigen comprising the structure of Formula (I), including one or more O3b-antigen mannose homopolymer repeating units, wherein Formula (I) is: MeP?3)-?-D-Manp-(1?2)-?-D-Manp-(1?3)-?-D-Manp-(1?[3)-?-D-Manp-(1?2)-?-D-Manp-(1?3)-?-D-Manp-(1?]n wherein MeP is methyl phosphate; and n is 0-50. The invention further provides for a pharmaceutical or diagnostic preparation comprising said antibody, and a method of producing said antibody.
    Type: Application
    Filed: June 30, 2016
    Publication date: November 1, 2018
    Applicant: ARSANIS BIOSCIENCES GMBH
    Inventors: Valeria SZIJARTO, Gábor NAGY, Katharina HARTL, Luis GUACHALLA, Eszter NAGY
  • Publication number: 20180066041
    Abstract: The invention provides for an isolated antibody that specifically recognizes a galactan-III epitope of the lipopolysaccharide (LPS) O-antigen structure of Klebsiella pneumoniae , which epitope is incorporated in galactan-III repeating units, wherein the galactan-III repeating unit is a branched galactose homopolymer of Formula (I). The invention further provides for a pharmaceutical or diagnostic preparation comprising said antibody, and a method of producing said antibody.
    Type: Application
    Filed: November 3, 2015
    Publication date: March 8, 2018
    Inventors: Valeria SZIJÁRTO, Gábor NAGY, Luis GUACHALLA, Zehra VISRAM, Eszter NAGY, Jolanta Katarzyna LUKASIEWICZ
  • Patent number: 9849169
    Abstract: The subject relates to an isolated antibody that specifically binds to O25b antigen of multi drug resistant (MDR) E. coli strains, its medical and diagnostic use, method of producing the antibody, including an isolated nucleotide sequence, plasmids and host cells as used in the production of the antibody; and further an isolated epitope recognized the specific antibody.
    Type: Grant
    Filed: January 17, 2014
    Date of Patent: December 26, 2017
    Assignee: ARSANIS Biosciences GmbH
    Inventors: Eszter Nagy, Gábor Nagy, Valéria Szijárto, Zoltán Magyarics, Irina Mirkina, Luis Guachalla, Adriana Badarau, Gerhild Zauner, Jolanta Lukasiewicz
  • Publication number: 20170145079
    Abstract: The invention refers to an isolated antibody that specifically binds to O25b antigen of E. coli strains comprising at least an antibody heavy chain variable region (VH), which comprises any of the CDR1 to CDR3 sequences as listed in FIG. 1, and optionally further comprising an antibody light chain variable region (VL), which comprises any of the CDR4 to CDR6 sequences as listed in FIG. 1, or functionally active CDR variants of any of the forgoing CDR 1-6 sequences.
    Type: Application
    Filed: December 19, 2014
    Publication date: May 25, 2017
    Applicant: ARSANIS BIOSCIENCES GMBH
    Inventors: Eszter NAGY, Gabor NAGY, Valeria SZIJARTO, Luis GUACHALLA, Maximiliano VASQUEZ
  • Publication number: 20170087236
    Abstract: The subject relates to an isolated antibody that specifically binds to O25b antigen of multi drug resistant (MDR) E. coli strains, its medical and diagnostic use, method of producing the antibody, including an isolated nucleotide sequence, plasmids and host cells as used in the production of the antibody; and further an isolated epitope recognized the specific antibody.
    Type: Application
    Filed: December 9, 2016
    Publication date: March 30, 2017
    Applicant: ARSANIS BIOSCIENCES GMBH
    Inventors: Eszter NAGY, Gábor NAGY, Valéria SZIJÁRTO, Zoltán MAGYARICS, Irina MIRKINA, Luis GUACHALLA, Adriana BADARAU, Gerhild ZAUNER, Jolanta LUKASIEWICZ
  • Publication number: 20150322138
    Abstract: The subject relates to an isolated antibody that specifically binds to O25b antigen of multi drug resistant (MDR) E. coli strains, its medical and diagnostic use, method of producing the antibody, including an isolated nucleotide sequence, plasmids and host cells as used in the production of the antibody; and further an isolated epitope recognized the specific antibody.
    Type: Application
    Filed: January 17, 2014
    Publication date: November 12, 2015
    Inventors: Eszter NAGY, Gábor NAGY, Valéria SZIJÁRTO, Zoltán MAGYARICS, Irina MIRKINA, Luis GUACHALLA, Adriana BADARAU, Gerhild ZAUNER, Jolanta LUKASIEWICZ